Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2009;53:617-623
Published online before print February 16, 2009, doi: 10.1161/HYPERTENSIONAHA.108.120154
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
53/4/617    most recent
HYPERTENSIONAHA.108.120154v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muntner, P.
Right arrow Articles by Whelton, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muntner, P.
Right arrow Articles by Whelton, P. K.
Related Collections
Right arrow Primary prevention
Right arrow Clinical Studies
Right arrow Other Treatment
Right arrow Epidemiology
Right arrowRelated Article

(Hypertension. 2009;53:617.)
© 2009 American Heart Association, Inc.


Original Articles

Antihypertensive Prescriptions for Newly Treated Patients Before and After the Main Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Guidelines

Paul Muntner; Marie Krousel-Wood; Amanda D. Hyre; Erin Stanley; William C. Cushman; Jeffrey A. Cutler; Linda B. Piller; Gary A. Goforth; Paul K. Whelton

From the Department of Community and Preventive Medicine (P.M.), Mount Sinai School of Medicine, New York, NY; Ochsner Clinic Foundation and Tulane University Schools of Medicine and Public Health and Tropical Medicine (M.K-W., E.S.), New Orleans, La; University of Pennsylvania School of Medicine (A.D.H.), Philadelphia; Memphis Veterans Affairs Medical Center (W.C.C.), Memphis, Tenn; National Heart, Lung, and Blood Institute (J.A.C.), Bethesda, Md; University of Texas Health Science Center School of Public Health (L.B.P.), Houston; Montgomery Center for Family Medicine (G.A.G.), Greenwood, SC; and Loyola University Medical Center (P.K.W.), Maywood, Ill.

Correspondence to Paul Muntner, Department of Community and Preventive Medicine, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10016. E-mail paul.muntner{at}mssm.edu

Main results of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial were published in December 2002. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, published in May 2003, recommended thiazide-type diuretics as initial pharmacological treatment alone or in combination with another drug in most patients with hypertension. To assess changes from before to after these publications, we compared antihypertensive medication prescriptions filled by patients who initiated pharmacological antihypertensive treatment in a large managed care organization during 3 time periods: (1) July 1, 2001, to June 30, 2002 (before these publications; n=1354); (2) July 1, 2003, to June 30, 2004 (to assess short-term changes; n=1542); and (3) July 1, 2004, to June 30, 2005 (to assess extended changes; n=1865). The percentage of patients initiating antihypertensive treatment with a thiazide-type diuretic increased from 30.6% to 39.4% (P<0.001) between 2001–2002 and 2003–2004, and the increase was maintained at 36.5% in 2004–2005 (P<0.001 compared with 2001–2002 and P=0.33 compared with 2003–2004). Among patients without diabetes mellitus, renal disease, a history of myocardial infarction, or heart failure, the percentage initiating pharmacological antihypertensive treatment with a thiazide-type diuretic increased from 33.1% in 2001–2002 to 43.4% in 2003–2004 (P<0.001) and remained increased (41.0%) in 2004–2005 (P<0.001 and P=0.23 compared with 2001–2002 and 2003–2004, respectively). Despite a sustained increase in the use of thiazide-type diuretics, this study indicates that an opportunity exists to increase adherence to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines.


Key Words: hypertension • antihypertensive agents • thiazide diuretics • clinical trials • epidemiology


Related Article:

Postgame Wrap of the Ultimate Blood Pressure Megatrial: Did It Score an ALLHAT Trick or Was It "Three Strikes and You’re Out?"
Ross D. Feldman and Finlay A. McAlister
Hypertension 2009 53: 595-597. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
CirculationHome page
A. V. Chobanian
Impact of Nonadherence to Antihypertensive Therapy
Circulation, October 20, 2009; 120(16): 1558 - 1560.
[Full Text] [PDF]


Home page
Clin TrialsHome page
L. K. Bartholomew, W. C Cushman, J. A Cutler, B. R Davis, G. Dawson, P. T Einhorn, J. F Graumlich, L. B Piller, S. Pressel, E. J Roccella, et al.
Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project
Clinical Trials, August 1, 2009; 6(4): 329 - 343.
[Abstract] [PDF]


Home page
Eur Heart JHome page
F. A. McAlister, R. D. Feldman, K. Wyard, R. Brant, N. R.C. Campbell, and for the CHEP Outcomes Research Task Force
The impact of the Canadian Hypertension Education Programme in its first decade
Eur. Heart J., June 2, 2009; 30(12): 1434 - 1439.
[Full Text] [PDF]


Home page
HypertensionHome page
R. D. Feldman and F. A. McAlister
Postgame Wrap of the Ultimate Blood Pressure Megatrial: Did It Score an ALLHAT Trick or Was It "Three Strikes and You're Out?"
Hypertension, April 1, 2009; 53(4): 595 - 597.
[Full Text] [PDF]